本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Transforming CX with Scalable, Responsible AI and Enterprise Integration SAN ANTONIO, Oct. 29, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that NCS has received the 2025 Singapore Customer Value Leadership Recognition in the contact center technology services industry for its outstanding achievements in delivering human-centric AI transformation, responsible innovation, and measurable operational outcomes. This recognition highlights NCS's leadership in redefining digital customer experiences through scalable AI platforms, enterprise-grade integration, and strategic collaboration with public and private sector clients. This recognition highlights NCS’s leadership in redefining digital customer experiences through scalable AI platforms, enterprise-grade integration, and strategic collaboration with public and private sector clients. NCS demonstrates its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. "Frost & Sullivan finds that NCS empowers organizations to reimagine CX by embedding generative AI, conversational automation, and knowledge-augmented resources into the customer's existing service functions. The company does so by leveraging its modular AI accelerators and deep expertise in enterprise integration," said Krishna Baidya, Senior Director - ICT Practice, Asia-Pacific at Frost & Sullivan. Guided by a long-term strategy centered on responsible innovation, co-creation, and regional relevance, NCS has positioned itself as a trusted transformation partner for governments and enterprises alike. Its AI-first model is designed to deliver high-impact outcomes across citizen services, advisory ecosystems, and automation functions, enabling clients to scale with confidence in a fast-changing digital landscape. Innovation remains central to NCS's approach. Its suite of AI accelerators - Conversational AI, Knowledge-Augmented AI, GenAI@Scale, and Agentic AI - forms the backbone of customized, compliant, and efficient contact center deployments. NCS deployed an integrated generative AI solution built on Amazon Bedrock and orchestrated through its Ins8.ai platform, combining speech recognition and intelligent call summarization at Ministry of Manpower Singapore's Contact Centre. Its speech-to-text engine achieved 95% accuracy in understanding Singaporean and regional accents. The use of Claude Instant LLM for call summarization with 99% accuracy, saw a 10% reduction in average handling time (AHT), a >50% reduction in after-call administrative work. This project reinforces how generative AI can augment human agents, enabling empathy-driven interactions while streamlining backend operations. NCS's focus on customer-centric design and agile prototyping is further supported by Tesseract, NCS' Innovation Centre in Singapore, a space where clients can explore AI use cases through real-world experimentation. This collaborative model not only accelerates ROI but also builds long-term confidence in AI adoption, aligning innovation delivery with organizational priorities. The company's commitment to responsible AI is evident in its leadership within Singapore's AI governance ecosystem. As a co-developer of the Generative AI Centre of Excellence for Public Good and an active participant in the IMDA Global Assurance Pilot, NCS embeds principles of ethical AI, privacy protection, and bias mitigation into every deployment. This emphasis on trustworthy innovation strengthens its ability to serve highly regulated sectors such as public services and finance. Frost & Sullivan commends NCS for setting a high standard in strategic execution, market responsiveness, and value-driven innovation. The company's ability to blend technology with human insight not only elevates contact center performance but also redefines the role of AI in customer engagement. Its internal focus on workforce empowerment—through platforms like NCSgpt and a growing community of over 3,000 AI practitioners—ensures that its innovations are both sustainable and grounded in real-world expertise. Each year, Frost & Sullivan presents the Customer Value Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition is reserved for forward-thinking organizations that drive tangible impact through differentiated solutions and exceptional execution. Frost & Sullivan Best Practices recognitions celebrate companies in regional and global markets that demonstrate superior performance in leadership, technological innovation, and strategic development. Market participants are evaluated through in-depth interviews, data analysis, and extensive research to identify best-in-class practices that shape the industry's future. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini SinghE: Tarini.Singh@frost.com About NCS NCS, a subsidiary of Singtel Group, is a leading technology services firm with presence in Asia Pacific which partners with governments and enterprises to advance communities through technology. Combining the experience and expertise of its 13,000-strong team across 56 specialisations, NCS provides differentiated and end-to-end technology services to clients with its NEXT capabilities in digital, data, cloud and platforms, as well as core offerings in applications, infrastructure, engineering and cybersecurity. NCS also believes in building a strong partner ecosystem with leading technology players, research institutions and start-ups to support open innovation and co-creation. For more information, visit ncs.co.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the launch of its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIx™ AI platform, built upon the Harbour Mice® platform. This platform establishes a closed-loop process integrating AI design, intelligent screening, and wet-lab validation. The announcement was made at the company's Global R&D Day 2025 event in Shanghai. During the event, the Global AI + Pharmaceutical Ecosystem Alliance was also officially launched. The alliance brings together leading expertise, cutting-edge technologies, and resources from various sectors, aiming to systematically reshape the entire drug R&D process through artificial intelligence technologies, accelerating the development of innovative therapies for the benefit of patients worldwide. AI-Driven Precision for Faster and More Accurate Target Identification The newly released AI HCAb Model establishes a closed-loop workflow that integrates AI-driven sequence generation, design and screening, and wet-lab validation. This end-to-end process transforms antibody discovery from blind screening to AI-driven intelligent selection, dramatically improving efficiency and accuracy in antibody discovery. HCAb, known for its simple structure and low molecular weight, holds strong potential for advanced applications like bispecific/multi-specific antibodies, ADCs, CAR-T, and mRNA therapies. However, conventional human VH domains struggle to maintain stability without VL pairing. Harbour BioMed's Harbour Mice® platform — the world's first transgenic mouse platform that produces fully human functional HCAb — laid the foundation for overcoming this challenge. The key AI design lies in accurately identifying functional, autonomous HCAbs from vast datasets, given the high structural and sequential similarity between HCAb VH sequences and those of conventional (H2L2) antibodies. Harbour BioMed's HCAb generation model is trained on 9 million NGS-derived HCAb sequences and extensive public data. Using a fine-tuned protein large language model, it enables de novo generation of high-potential HCAb sequences, with secondary optimization for target specificity. These AI-generated sequences then undergo a multi-stage intelligent screening process, which includes: AI Classification Model to filter non-HCAb sequences Multimodal AI Developability Prediction Model (achieving SOTA performance) to assess key developability parameters such as stability, solubility, and aggregation tendency Only candidates that pass rigorous screening proceed to synthesis and wet-lab validation. AI HCAb Model Delivers Higher Binders Diversity and Binding Success Rate The AI HCAb Model demonstrated a tenfold increase in candidate generation and significantly improved success rates. Data show that among 107 de novo generated binder sequences produced by AI HCAb model, 78.5% successfully hit the target, while 20 molecules were further validated in wet-lab assays, demonstrating high activity, purity, yield, and specificity. These AI-designed binders demonstrated outstanding developability profiles, with an average yield exceeding 700 mg/L. Multiple candidate sequences showed nanomolar-level binding affinity while maintaining binding activity against relevant targets in both humans and cynomolgus monkeys. Accelerating the Development of Next-Generation Therapies Harbour BioMed's AI platform is designed as a self-evolving innovation flywheel driven by continuous learning and feedback: AI design – automated validation – AI re-learning. This iterative process enables generative AI to create diverse new molecules, while high-throughput automation rapidly characterizes and feeds back experimental data to continuously enhance model intelligence and R&D efficiency. With this foundation, the AI HCAb Model is expected to accelerate applications of fully human HCAbs across next-generation therapeutic areas — including multi-specific antibodies, XDCs, in vivo CAR-T, and inhaled or oral large-molecule drugs — helping redefine the landscape of biologics discovery. Building the Future AI + Pharmaceutical Ecosystem At the event, Harbour BioMed also announced the official establishment of the Global AI + Pharmaceutical Ecosystem Alliance, which brings together leading experts, technology partners, and investors to reshape the entire drug discovery pipeline through AI innovation. The alliance has gained strong support from government bodies, industry associations, and investors including Fortera Capital, Insilico Medicine, Molecular Mind, Evinova, INNOVEL, Fenglin Group, Taimei Technology, EClinCloud, Deep Intelligent Pharma, and Harbour BioMed. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, said: "The Global AI + Pharmaceutical Ecosystem Alliance aims to create an open, collaborative, and win–win ecosystem. Through shared value and collective innovation, we seek to address the toughest challenges in drug discovery and bring transformative therapies to patients faster and more effectively." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.
New benchmark results confirm the Clarifai Reasoning Engine on Vultr's GPU clusters delivers unprecedented speed, efficiency, and scalability for next-gen AI workloads WASHINGTON, Oct. 28, 2025 /PRNewswire/ -- Clarifai, a global leader in AI and pioneer of the full-stack AI platform, and Vultr, the world's largest privately held cloud computing platform, today announced new benchmark results demonstrating unprecedented inference speed and cost efficiency on GPUs. The announcement comes as the two companies showcase their collaboration at the Vultr booth during NVIDIA GTC Washington, D.C., taking place October 28–30. The joint results highlight the Clarifai Reasoning Engine, optimized for agentic AI inference, running on Vultr's large-scale dedicated GPU clusters. Independent testing by Artificial Analysis showed the Clarifai Reasoning Engine achieving 544 tokens per second, 0.36 seconds time to first token, and an industry-leading $0.16 per million tokens on the GPT-OSS-120B model—outpacing every GPU-based inference platform tested, and rivaling specialized ASIC accelerators. "Clarifai's benchmark-topping performance is a testament to what's possible when software innovation meets cloud engineering excellence," said Kevin Cochrane, CMO of Vultr. "Our GPU clusters deliver extraordinary inference speed and efficiency while keeping costs under control. Together with Clarifai, we're enabling organizations to develop competitive, high-performance AI solutions faster than ever before." "Vultr's GPU infrastructure is a cornerstone of how we help customers unlock the full potential of the Clarifai Reasoning Engine," said Matthew Zeiler, Founder & CEO at Clarifai. "As organizations build AI workloads and agentic systems, they need performance and cost efficiency without compromising reasoning quality. Vultr provides the speed and reliability that make those outcomes possible." The latest benchmarks are part of the Clarifai 11.9 release, which introduces expanded capabilities for building and deploying advanced AI systems, including: Added new Vultr cloud instances on NVIDIA HGX B200 and NVIDIA GH200 Grace Hopper™ Superchips. Toolkit compatibility for vLLM, LMStudio, and Hugging Face, enabling seamless model initialization and management. New model releases, including Qwen3-Next-80B-A3B-Thinking and Qwen3-30B-A3B-Instruct, further expanding Clarifai's model-agnostic ecosystem. Built for enterprise-scale workloads, the Clarifai Reasoning Engine continuously optimizes kernels, batching, and memory use based on workload behavior, improving performance over time without sacrificing accuracy. It supports any large reasoning model, allowing customers to bring their own models and achieve similar levels of throughput and efficiency. Clarifai and Vultr are setting a new standard for AI inference performance, scalability, and cost control, enabling developers and enterprises to accelerate innovation in reasoning, agentic systems, and generative AI. Visit Clarifai and Vultr at booth #453 to learn more. About ClarifaiClarifai is a global leader in AI and the pioneer of the full-stack AI platform that helps organizations, teams, and developers build, deploy, and operationalize AI at the highest scale and availability. Clarifai's cutting-edge AI platform supports today's modern AI technologies like Large Language Models (LLMs), Large Vision Models (LVMs), Retrieval Augmented Generation (RAG), automated data labeling, high-volume production inference, and more. Founded in 2013, Clarifai is available in cloud, on-premises, or hybrid environments and has been used to build more than 1.5 million AI models, serving more than 500,000 users across 170 countries. Learn more at www.clarifai.com. For more information or media requests, contact: pr@clarifai.com. About VultrVultr is on a mission to make high-performance cloud infrastructure easy to use, affordable, and locally accessible for enterprises and AI innovators around the world. Vultr is trusted by hundreds of thousands of active customers across 185 countries for its flexible, scalable, global Cloud Compute, Cloud GPU, Bare Metal, and Cloud Storage solutions. Founded by David Aninowsky and self-funded for over a decade, Vultr has grown to become the world's largest privately held cloud infrastructure company.
Seven consecutive years of winning the “Most Innovative Product/Service Award”, demonstrating consistent product innovation; Once again receiving all digital categories, reflecting the company’s comprehensive digital successHONG KONG SAR - Media OutReach Newswire - 24 October 2025 – FWD Hong Kong ("FWD") is proud to announce its exceptional performance at the prestigious Hong Kong Insurance Awards 2025, securing nine accolades, including six grand awards and three top-three recognitions, leading the industry in innovation, digital transformation and social impact. This year, FWD has once again received all digital-related categories, reinforcing its undisputed leadership in digital innovation. Ken Lau, Managing Director, Greater China and Hong Kong Chief Executive Officer, FWD said, "We are immensely proud and deeply honoured by the recognition at the Hong Kong Insurance Awards 2025. These nine awards are a powerful testament to the relentless dedication and innovative spirit of our entire FWD team, who consistently strive to put our customers first and challenge industry norms. FWD Group began trading as a publicly listed company on the Hong Kong Stock Exchange in July, marking a defining milestone. In the first half of this year, FWD Group demonstrated significant growth momentum in the Hong Kong and Macau markets, with new business annual premium equivalent (APE) more than doubling year-on-year. Furthermore, FWD Hong Kong's financial strength rating was upgraded1. These accolades and robust business performance affirm that our customer-led and tech-enabled approach is truly changing the way people feel about insurance, showcased through our leadership in product innovation, digital marketing, talent development, and operational excellence." FWD Hong Kong is proud to announce its exceptional performance at the prestigious Hong Kong Insurance Awards 2025, securing nine accolades, including six grand awards and three top-three recognitions, leading the industry in innovation, digital transformation and social impact. Customer insight recognised with "Most Innovative Product/Service Award" The recognition underscores FWD's sustained ability to drive product innovation, as we strive to develop solutions that bridge the protection gaps in the market and enhance accessibility. "Crisis EasyGo Series" was awarded the grand award in the "Most Innovative Product/Service Award – Health" category. This marks the seventh consecutive year FWD's health protection products have been acknowledged in this prestigious category, underscoring the team's ongoing innovative mindset in developing high-quality health protection. The series offers first-in-Hong Kong solutions2 for individuals with minor chronic conditions, cancer survivors, and those who have suffered from heart diseases or stroke. It simplifies access with easy application with as few as two underwriting questions3 and no medical exam required and extends care beyond financial protection through the FWD Care ecosystem. FWD's "Imperial Fortune Insurance Plan" (Imperial Fortune) was awarded the grand award in the "Most Innovative Product/Service Award – Life Insurance" category. This product is a protection-oriented Indexed Universal Life plan designed for eligible professional investors, offering a first-in-Hong Kong4 uncapped crediting interest rate, high life insurance leverage, multiple guarantees, and high flexibility. It provides high-net-worth clients with a robust solution for life insurance protection and wealth growth. Digital leadership continuously enhancing customer experience FWD has once again received all digital-related categories this year, reinforcing its undisputed leadership in digital innovation and customer engagement. This achievement underscores the company's consistent commitment to leading the industry's digital transformation, leveraging technology to enhance customer experience, engagement, and operational efficiency. FWD was recognised among the top-three in the "Excellence in Digital Transformation Award" for its innovative services powered by artificial intelligence (AI). Recognising significant market demand, FWD established a WeChat ecosystem. This ecosystem encompasses an AI platform and a 'Video Factory', which assist tied agents in providing personalised contents and sales strategies. The 'Video Factory' further empowers tied agents to create AI-powered videos in just five minutes, boosting productivity. Furthermore, "FWD Online Go Beyond" campaign was awarded the grand award in the "Outstanding Digital Marketing Campaign Award". This campaign strategically addresses the evolving Hong Kong insurance market, where customers demand simple, online-first experiences. The initiative has achieved remarkable results, with both website traffic and conversion rates significantly increasing, delivering a smoother and more satisfying experience for more customers. Tech-enabled leadership in operational stability and risk management FWD's first-time winning for the "Outstanding Risk Management Award" recognises FWD's ongoing commitment to strengthening its enterprise risk management framework. Its "Climate Risk Management Initiatives" align with Insurance Authority's growing emphasis on managing climate risk, while the "Operational Resilience Programme" ensures essential service continuity under stress scenarios. The shortlisting in the top three for the "Outstanding Claims Management Award", affirming FWD's efforts to maintain the highest standards of integrity and efficiency in claims processing. The team's robust AI-powered "FWA (Fraud, Waste and Abuse)" Detection Model leverages advanced analytics to detect and prevent fraudulent activities. FWD’s multiple accolades at the Hong Kong Insurance Awards 2025 affirm its leadership in continuous innovation, digital transformation, and community care. Fostering professional development and community engagement FWD Hong Kong's success is deeply rooted in its commitment to nurturing talent, fostering professional growth, and making a positive contribution to the community. FWD won in the "Outstanding Training & Development Award", demonstrating FWD's forward-thinking approach to talent development. Through diverse and internationally-minded training, FWD cultivates leaders capable of navigating future challenges. Kenny Tai, Agency Director, won "Outstanding Community Intermediary of the Year". He led his agency team in participating in numerous charitable activities, setting an example for FWD's commitment to community care and inspiring colleagues to integrate social responsibility into their professional development. Kristy Tsang, Agency Director, was recognised as a top-three finalist for "Outstanding Young Professional of the Year – Intermediary". She leads her agency team with professionalism and an innovative spirit, and her potential as a future leader in the insurance industry is highly affirmed. FWD's multiple accolades at the Hong Kong Insurance Awards 2025 affirm its leadership in continuous innovation, digital transformation, and community care. Staying customer-led, FWD remains committed to providing innovative insurance products and services, investing resources in talent cultivation and community care, and changing the way people feel about insurance. [1] FWD Group Holding Limited, according to its financial results for the first six months ended 30 June 2025. [2] Per a comparison made on 30 Sep 2024 among the critical illness insurance plans of key insurers available in Hong Kong, FWD is the first insurance company in Hong Kong to launch a participating whole life critical illness plan with Special Disease Benefit, Life Impact Benefit and Extended Critical Medical Care Benefit for those recovered from cancer or suffered from heart diseases or stroke under simplified underwriting approach. [3] The Insured can be covered under Crisis EasyGo – UCanCover or Crisis EasyGo – UStillCover provided that he/she passes the underwriting questions. For relevant underwriting requirements, terms and conditions, please refer to the complete underwriting questions. [4] Per a comparison of indexed universal life products from major insurers in Hong Kong, conducted by FWD in July 2025. Appendix - List of FWD Hong Kong's wins: Award categories Awards Awardees/winning items Project highlights Most Innovative Product/Service Award – Health (Awarded for seven consecutive years) Grand award Crisis EasyGo Series The Crisis EasyGo Series critical illness protection plans, including UCanCover designed specifically for cancer survivors and UStillCover for those who have suffered from heart diseases or stroke, offer simplified underwriting with as few as two questions, no medical exam, lifetime coverage for up to 115 diseases, and an expanding partnership with a medical partner for professional rehabilitation support. Most Innovative Product/Service Award – Life Insurance Grand award Imperial Fortune Insurance Plan The Imperial Fortune Insurance Plan is an indexed universal life product for eligible professional investors. Offering life protection and wealth appreciation, it strengthens FWD's HNW offerings, addressing diverse needs in wealth growth, legacy planning, and life protection. Outstanding Community Intermediary of the Year (Awarded for three consecutive years) Grand award Kenny Tai, Agency Director at FWD Kenny joined FWD in 2015, and apart from his client services, as Vice Chairman of ACT Charity Limited, he has spearheaded over 40 charitable activities, benefiting more than 8,000 beneficiaries for various causes. Outstanding Digital Marketing Campaign Award (Awarded for four consecutive years) Grand award FWD Online Go Beyond FWD leverages a fully data‑driven communication strategy to focus on high‑potential target segments most likely to engage and convert. By concentrating resources and aligning with their evolving needs, it builds deeper connections that drive long‑term loyalty, sustainable growth, and increased market share. Outstanding Risk Management Award Grand award Climate Risk Management Initiatives and Operational Resilience Programme FWD's Climate Risk Management Initiatives and Operational Resilience Programme reinforce enterprise risk management, earning the award for strengthening governance, resilience and sustainability in a rapidly evolving regulatory and environmental landscape. Outstanding Training & Development Award (Awarded for four consecutive years) Grand award ESG Development Programme FWD partners with INSEAD, Fudan University, Deloitte and EY to deliver leadership, tax planning and NextGen talent programmes, cultivating leaders, enhancing sales excellence and developing future financial planning professionals. Excellence in Digital Transformation Award (Awarded for five consecutive years) Top-three finalist Digital Products: WeChat Client Hub Video Factory Short Video Proposal The WeChat Client Hub supports agents serving customers by enhancing engagement and team management through an AI-powered platform and social channel. The integrated 'Video Factory' tool further empowers agents to develop personal brands and connect with customers via WeChat. Outstanding Claims Management Award Top-three finalist FWA (Fraud, Waste and Abuse) FWD's AI-powered claims models generate FWA Risk Scores and Suspicious Analytical Signals, achieving 52% fraud detection and enhancing service quality and competitiveness. Outstanding Young Professional of the Year – Intermediary Top-three finalist Kristy Tsang, Agency Director at FWD Kristy has over a decade of experience in the insurance industry, achieving Million Dollar Round Table (MDRT) qualification for 10 consecutive years, cultivating 13 MDRT members, and becoming FWD's first Distinguished Salesperson Award (DSA) Top 5 winner. She actively promotes financial literacy, leads community service, and inspires professionalism through industry competitions. Hashtag: #FWDThe issuer is solely responsible for the content of this announcement.About FWD Hong KongFWD Hong Kong is part of the FWD Group (1828.HK), a pan-Asian life and health insurance business that serves approximately 34 million customers across 10 markets, including BRI Life in Indonesia. FWD Hong Kong has been assigned strong financial ratings by international agencies. It offers life and medical insurance, employee benefits, and financial planning. FWD's customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828. For more information about FWD Hong Kong, please visit www.fwd.com.hk.
Ascendion Named Global Leader: ISG ranks Ascendion among the world's best in Generative AI strategy and delivery. Turning Vision Into Velocity: AAVA™, the Agentic AI platform, transforms strategy into measurable enterprise impact. Humans + Agents, Working Better Together: Ascendion's agentic model boosts speed, quality, and trust across engineering. Rising Star to Market Leader: Consecutive ISG honors underscore Ascendion's rapid ascent in AI-powered software engineering. BASKING RIDGE, N.J., Oct. 23, 2025 /PRNewswire/ -- Ascendion, a leader in AI-powered software engineering, has been recognized by ISG for redefining how enterprises deliver on the promise of AI — translating strategy into tangible business outcomes. Today, the company announces its recognition as a Global Leader for the second consecutive year in the ISG Provider Lens® Generative AI Services 2025 study. Ascendion earned top tier leadership positions in two categories: Strategy & Consulting Services and Development & Deployment Services. These results reaffirm the company's position at the forefront of operationalizing Generative AI for enterprises. Access the full ISG report here. Ascendion Recognized as a Global Leader in the ISG Provider Lens® for Generative AI Services 2025 As organizations struggle to move beyond experimentation, Ascendion's Agentic AI platform, AAVA™, collapses the distance between strategy and execution, turning intent into engineered outcomes. By embedding autonomous agents and automation into live delivery pipelines, the company helps close the gap between vision and impact. Real-world results include up to 60% effort savings in data analysis for Fortune 50 banks, 50% productivity gains in automated form processing, and 40% faster time-to-market in complex software programs, all delivered through a human-in-the-loop model that ensures quality and trust. "Ascendion operationalizes GenAI through a platform-centric model that integrates agentic workflows, modular delivery, and embedded consulting. Its structured approach enables scalable transformation across engineering, strategy, and compliance-driven environments with measurable alignment to enterprise adoption patterns," said Gowtham Kumar Sampath, Assistant Director and Principal Analyst, ISG. Unlike advisory only models that stop at the whiteboard, Ascendion's Agentic design blends automated lifecycle execution with strategic human guidance, ensuring people remain the architects of innovation. This human plus agent model is powered by AAVA™, the company's platform that improves work along the software development lifecycle with orchestrated agents, and reinforced by METal, Ascendion's intelligent talent orchestration engine. Together, they modernize enterprise systems faster, scale operations smarter, and sustain full governance across the engineering fabric. "Our recognition by ISG as a global leader reflects the strength of our vision, platforms, and people," said Karthik Krishnamurthy, Chief Executive Officer, Ascendion. "We are leading enterprises beyond AI pilots to sustained business value. With our Engineering to the Power of AI platforms and models, we are changing how the industry delivers services and value. Our clients gain innovation velocity, economic advantage, and business impact needed to lead in the agentic era." Ascendion continues to perform strongly across ISG assessments, demonstrating consistent momentum across its digital and AI-powered offerings. Last year, the company was recognized as a Rising Star in the 2024 ISG Provider Lens® for Digital Engineering, and earlier this year, Ascendion earned Rising Star positions in two quadrants of the 2025 ISG Provider Lens® for Digital Engineering Services. Ascendion forges ahead to lead the new era of Engineering to the Power of AI. The company is delivering on its mission to unlock enterprise value by combining intelligent agents, modern engineering methods, and human ingenuity. About Ascendion Ascendion is a leader in AI-powered software engineering, helping businesses innovate faster, smarter, and with greater impact. We partner with Global 2000 clients across North America, APAC, and Europe to solve complex challenges in data, experience design, software product engineering, and workforce transformation. Powered by expert engineers, thousands of AI agents, and our Engineering to the Power of AI™ (EngineeringAI) method, we deliver measurable outcomes that build trust, unlock value, and accelerate growth. Learn more at ascendion.com. Engineering to the Power of AI™, AAVA™, EngineeringAI, Engineering to Elevate Life™, DataAI, ExperienceAI, Platform EngineeringAI, Product EngineeringAI, Quality EngineeringAI, and GCCAI are trademarks or service marks of Ascendion®. AAVA™ is pending registration. Unauthorized use is strictly prohibited. About ISGISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 800 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals, operating in more than 20 countries – a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit www.isg-one.com Media Contact: Vinutha Naik, Ascendion, vinutha.naik@ascendion.com, +91 97313 39000
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has successfully met the primary endpoint in its Phase III clinical trial. MTS-004 is China's first drug candidate designed by AI-driven formulation technologies to complete Phase III development, and the first and only therapy for Pseudobulbar Affect (PBA) in the country to reach this milestone—representing a major step toward addressing an unmet clinical need in neurological disorders. MTS-004 is a novel oral formulation designed for the treatment of PBA, utilizing METiS TechBio's proprietary AiTEM platform to develop orally disintegrating tablet (ODT). Tailored for patients frequently experiencing dysphagia, MTS-004 dissolves rapidly in the mouth without the need for water, offering a pleasant taste and significantly improving medication adherence and patient experience. Pseudobulbar Affect (PBA)—commonly known as "pathological laughing and crying"—is a neurological condition characterized by sudden, involuntary, and inappropriate episodes of laughing or crying that do not match a patient's true emotional state. PBA frequently occurs secondary to central nervous system disorders such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury (TBI), or Parkinson's disease (PD). The condition can severely impair social functioning and quality of life, while exacerbating the burden of underlying neurological diseases. The AiTEM platform, powered by METiS TechBio's proprietary NanoForge AI nanodelivery system, uses advanced algorithms to design and optimize pharmaceutical formulations. By integrating quantum chemistry and molecular dynamics simulations, AiTEM predicts drug–excipient interactions and generates nanoscale formulation optimization solutions to enhance solubility, bioavailability, and pharmacokinetic performance. In the case of MTS-004, AiTEM enabled predictive modeling that shortened the preclinical formulation optimization period from the industry average of 1–2 years to under 3 months. From program initiation to Phase III completion, MTS-004 completed a full development cycle of in months, significantly accelerating the path from discovery to clinical validation. The Phase III trial was led by Professor Dongsheng FAN, Chair of Neurology at the Peking University Third Hospital and a leading expert in ALS and neurodegenerative disorders. This randomized, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of MTS-004 in patients with PBA secondary to ALS, MS, stroke, TBI, or PD. The trial enrolled 264 patients across 48 top-tier hospitals nationwide over a period of 9.5 months, including Beijing Xuanwu Hospital, Beijing Tiantan Hospital, West China Hospital Sichuan University, The First Affiliated Hospital of China Medical University, The Second Affiliated Hospital of Zhejiang University School of Medicine, Jiangsu Provincial People's Hospital, Shandong Qianfoshan Hospital, Guangdong Second Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Renji Hospital of Shanghai Jiao Tong University, and Xiangya Hospital of Central South University. Currently, the only approved treatment worldwide for PBA is NUEDEXTA® in the U.S. MTS-004, classified in China as a Category 2.2 improved new drug, introduces an innovative ODT formulation that effectively addresses swallowing difficulties—an unmet need among PBA patients—and provides a user-friendly alternative to capsule formulations. Results from the Phase III study demonstrated that MTS-004 was safe, well-tolerated, and effective in reducing PBA symptoms in patients with neurological disorders. Therapeutic benefits were observable as early as week 2, with continued increases in symptom-free days and sustained improvement throughout the 12-week treatment period. MTS-004 achieved statistically significant improvements over placebo in: CNS-LS (Center for Neurologic Study–Lability Scale) total score, CGI-C (Clinical Global Impression of Change) and PGI-C (Patient Global Impression of Change), SF-36 Mental Health Index, reflecting enhanced emotional regulation and quality of life. Additionally, MTS-004 significantly improved CNS-BFS (Bulbar Function Scale) score, particularly in swallowing and drooling symptoms—critical complications in patients with motor neuron and central nervous system diseases. MTS-004 is expected to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in 2026 for the PBA indication. Following approval, post-marketing studies are planned to explore potential label expansion for the treatment of dysphagia. Professor Dongsheng FAN, Principal Investigator, commented: "Artificial intelligence is reshaping how new drugs are discovered and developed. The MTS-004 clinical trial was challenging to initiate but was completed with outstanding quality. Its ability to improve patients'quality of life—especially its clear impact on swallowing function—can reduce complications and may positively influence survival. While this study focused on ALS-related PBA, MTS-004 shows potential across broader neurological populations." Dr. Chris Lai, Co-founder and CEO of METiS TechBio, stated: "We extend our sincere gratitude to Professor Fan, all participating investigators and clinical staff, every patient and family, and the community supporting PBA research. AI's mission in medicine is to empower clinicians and race against diseases, driven by a deep understanding of unmet patient needs. That mission inspired our 38-month sprint from concept to Phase III completion. MTS-004 marks METiS TechBio's first end-to-end success from discovery to late-stage clinical validation—a foundation that will accelerate every pipeline that follows." About METiS TechBio Unlocking a healthier world through AI-driven nanotechnology. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed NanoForge, the world's first AI-drive nano-delivery platform and three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design. METiS' platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives.
A12 藝術空間
AI Platform
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
